The prognostic role of sentinel node dissection on biochemical recurrence-free survival rate of prostate cancer patients after robot-assisted radical prostatectomy

2017 ◽  
Vol 16 (3) ◽  
pp. e1857
Author(s):  
N. Grivas ◽  
E. Wit ◽  
A. Bex ◽  
K. Hendricksen ◽  
S. Horenblas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Rate ◽  
Biochemical Recurrence ◽  
Recurrence Free Survival ◽  
Node Dissection ◽  
Prognostic Role ◽  
Robot Assisted ◽  
Sentinel Node Dissection ◽  
Free Survival

Expression profile of standard and variants forms of CD44 related to prostate cancer behavior

2015 ◽  
Vol 30 (1) ◽  
pp. 49-55 ◽  
Author(s):  
Caio M. Moura ◽  
Jose Pontes ◽  
Sabrina T. Reis ◽  
Nayara I. Viana ◽  
Denis R. Morais ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Biochemical Recurrence ◽  
The Other ◽  
Control Group ◽  
Recurrence Free Survival ◽  
Cd44 Isoforms ◽  
Free Survival ◽  
Expression Levels

CD44 is a transmembrane glycoprotein and is regarded as a potential marker in various tumors. The aim of our study was to analyze the expression of the standard form of CD44 (CD44s) and its isoforms in localized prostate cancer (PCa), and to correlate these data with the classical prognostic factors and biochemical recurrence. Ninety-four surgical specimens were analyzed in this study. The expression levels of CD44s and all its 9 variants were analyzed by quantitative real time PCR (qRT-PCR). The control group consisted of 14 specimens from patients with benign prostatic hyperplasia. We correlated all the expression profiles with biochemical recurrence, as defined by a PSA >0.4 ng/mL in a mean follow-up period of 53.3 months. In PCa, CD44s was underexpressed and all the other isoforms were overexpressed. The mean expression level of most variants was higher in patients who had not recurred, and a higher expression of CD44v2 independently correlated with a better recurrence-free survival rate (p=0.045). This variant was also underexpressed in metastatic PCa cell lines. There was no correlation between the expression levels of any of the CD44 isoforms and the classical prognostic factors. We here demonstrated that PCa cases are characterized by a change in the expression of CD44, with a loss of CD44s and an overexpression of all the other CD44 variants. However, during cancer progression we found a loss of expression of all CD44 variants, and a correlation between higher expression of CD44v2 and a better recurrence-free survival rate. The understanding of the CD44 expression patterns in PCa could contribute to its use as a new prognostic marker.

scholarly journals High levels of DEPDC1B predict shorter biochemical recurrence‑free survival of patients with prostate cancer

2017 ◽  
Author(s):  
Shoumin Bai ◽  
Ting Chen ◽  
Tao Du ◽  
Xianju Chen ◽  
Yiming Lai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Recurrence Free Survival ◽  
Free Survival

scholarly journals Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival

2008 ◽  
Vol 14 (3) ◽  
pp. 758-763 ◽  
Author(s):  
Joseph R. Sterbis ◽  
Chunling Gao ◽  
Bungo Furusato ◽  
Yongmei Chen ◽  
Syed Shaheduzzaman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Cancer Tissues

scholarly journals Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Ksenija Limani ◽  
Fouad Aoun ◽  
Serge Holz ◽  
Marianne Paesmans ◽  
Alexandre Peltier ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Rate ◽  
High Risk ◽  
High Intensity ◽  
Biochemical Recurrence ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Localized Prostate Cancer ◽  
Single Session ◽  
Free Survival

Objectives. To assess the treatment outcomes of a single session of whole gland high intensity focused ultrasound (HIFU) for patients with localized prostate cancer (PCa).Methods. Response rates were defined using the Stuttgart and Phoenix criteria. Complications were graded according to the Clavien score.Results. At a median follow-up of 94months, 48 (44.4%) and 50 (46.3%) patients experienced biochemical recurrence for Phoenix and Stuttgart definition, respectively. The 5- and 10-year actuarial biochemical recurrence free survival rates were 57% and 40%, respectively. The 10-year overall survival rate, cancer specific survival rate, and metastasis free survival rate were 72%, 90%, and 70%, respectively. Preoperative high risk category, Gleason score, preoperative PSA, and postoperative nadir PSA were independent predictors of oncological failure. 24.5% of patients had self-resolving LUTS, 18.2% had urinary tract infection, and 18.2% had acute urinary retention. A grade 3b complication occurred in 27 patients. Pad-free continence rate was 87.9% and the erectile dysfunction rate was 30.8%.Conclusion. Single session HIFU can be alternative therapy for patients with low risk PCa. Patients with intermediate risk should be informed about the need of multiple sessions of HIFU and/or adjuvant treatments and HIFU performed very poorly in high risk patients.

Sign in / Sign up

Export Citation Format

Share Document